Business / Finance

RSS

Spherix 2011 net loss decreases to $3.5 million

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today reported financial results for the year ended December 31, 2011, and recent and upcoming business highlights.

29 Mar 2012

Relievant Medsystems secures $30M in Series D equity financing

Relievant Medsystems, Inc., a privately held medical device company pioneering the therapeutic use of basivertebral nerve ablation for the treatment of chronic axial low back pain, announced today that it has secured $30 million in a Series D equity financing to advance and expand the Company's worldwide clinical development programs.

29 Mar 2012

Luna to extend development and supply agreement with Intuitive Surgical

Luna Innovations Incorporated announced today that it will be extending its development work through 2012 under its development and supply agreement with Intuitive Surgical, Inc., as they work towards the integration of Luna's shape and position sensing technology into Intuitive's medical robotic products.

29 Mar 2012

International Isotopes 2011 revenue increases 55% to $9,462,012

International Isotopes Inc. announces the financial results for fiscal year ended December 31, 2011, and plans for a shareholder conference call to review these results and provide a general update on the business performance and plans of the Company in 2012.

29 Mar 2012

Merrimack prices initial public offering of 14,300,000 shares of common stock

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.

29 Mar 2012

Helix BioMedix 2011 revenue increases 122% to record $1.9 million

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the year ended December 31, 2011.

29 Mar 2012

Pernix fourth quarter net revenues increase 74% to $21.4 million

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, today announced financial results for the quarter and year ended December 31, 2011.

29 Mar 2012

Nepstar fourth quarter revenue increases 4.9% to RMB658.0M

China Nepstar Chain Drugstore Ltd., the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2011.

28 Mar 2012

Vermillion fourth quarter total revenues increase 152% to $868,000

Vermillion, Inc., a leading molecular diagnostics company, reported financial and operational results for the fourth quarter and full year ended December 31, 2011.

From Quest Diagnostics 27 Mar 2012

ImaginAb completes Series A financing

ImaginAb, Inc. a clinical-stage company developing in vivo imaging agents for Positron Emission Tomography (PET) based on antibody fragment technology, today announced the completion of a Series A financing – led by Novartis Venture Funds.

27 Mar 2012

Zotec Partners to manage billing operations for TRA Medical Imaging

Zotec Partners, an industry leading provider of specialized medical billing and practice management services for the hospital-based specialty market, announces today that it will manage all billing operations for TRA Medical Imaging, out of Tacoma, Wash.

26 Mar 2012

USANA Health Sciences expands into French and Belgium markets

USANA Health Sciences, Inc., a global nutritional supplements company, today announced the official opening of its France and Belgium markets. Bringing the company's international expansion to 18 countries worldwide, USANA's newest office will reside on the Champs-Elysees in Paris and will initially offer seven nutritional supplements and eight skin-care products.

26 Mar 2012

Valeant signs agreement to acquire Natur Produkt

Valeant Pharmaceuticals International, Inc. announced today that Valeant has signed an agreement to acquire Natur Produkt International, JSC, a specialty pharmaceutical company in Russia.

26 Mar 2012

TOLMAR, Impax Labs partner for alternative dosage form products

Impax Laboratories, Inc. and TOLMAR, Inc. today announced that they will collaborate on a multiproduct agreement for the development, supply and distribution of alternative dosage form products.

26 Mar 2012

BioLife fourth quarter total revenue increases 41% to $809,564

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced record revenue for the fourth quarter and full year 2011, and for the first time, provided initial guidance on management's outlook for the full year 2012.

26 Mar 2012

Patient Safety Technologies fourth quarter total revenues decrease to $2.7M

Patient Safety Technologies, Inc. today announced results for its fourth quarter and fiscal year 2011 ended December 31st, 2011.

26 Mar 2012

OncoSec to purchase $7.75M of securities in registered public offering

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, announced today that it has entered into definitive agreements with institutional investors to purchase $7.75 million of securities in a registered public offering.

26 Mar 2012

Asahi Kasei announces commencement of tender offer for ZOLL

Asahi Kasei Corporation, Japan's leading diversified chemical manufacturer with businesses in the health care, chemicals & fibers, homes & construction materials, and electronics sectors, announced today the commencement of a tender offer through its indirect wholly owned U.S. subsidiary Asclepius Subsidiary Corporation for all outstanding shares of common stock of ZOLL Medical Corporation for $93 per share, net to the seller in cash, without interest and less any required withholding taxes.

26 Mar 2012

BiO2 Medical completes $13.7M Series B round of funding

BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has recently completed its $13.7M Series B round of funding, which included the conversion of a $1M State of Texas Emerging Technology Fund (ETF) award.

26 Mar 2012

Islet Sciences acquires DTI

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced the closing of the acquisition of DiaKine Therapeutics, Inc., a biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes which is now the Company's wholly owned subsidiary.

26 Mar 2012